{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:57:31Z","timestamp":1788623851001,"version":"build-2803163510"},"reference-count":20,"publisher":"Oceanside Publications Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"\n Background:<\/jats:bold>\n Hereditary angioedema (HAE) is a rare, potentially life-threatening bradykinin-mediated disorder with limited pediatric treatment options and little comparative evidence. Icatibant, a bradykinin B2 receptor antagonist, has demonstrated efficacy in adults and has\n emerging evidence in children.\n Objective:<\/jats:bold>\n To evaluate and synthesize clinical evidence on the efficacy and safety of icatibant for acute HAE attacks in pediatric patients.\n Methods:<\/jats:bold>\n A literature search was performed by using medical literature data bases,\n clinical trial and research registries, and key journals through January 2026. The primary outcome was the time to onset of symptom relief. Secondary outcomes included the time to minimum symptoms, pain scores, adverse events, and feasibility of self- or caregiver administration. All included\n studies were nonrandomized, single-arm trials with heterogeneous designs and outcomes definitions; therefore, a meta-analysis was not performed, and all studies were descriptively evaluated.\n Results:<\/jats:bold>\n This systematic review identified three clinical studies of icatibant\n for acute HAE attacks in children ages 0 to 17 years. Three open-label, phase III studies, which included 43 pediatric patients were reviewed. Icatibant demonstrated rapid symptom relief, with a median onset at \u223c1 hour and minimum symptoms within 2 hours, although repeated dosing showed\n variability. Icatibant was well tolerated, with injection-site reactions as the most common adverse events and no serious treatment-related events. Self- or caregiver administration was feasible and effective in adolescents.\n Conclusion:<\/jats:bold>\n Icatibant was safe and effective\n in the pediatric studies, providing rapid symptoms relief and a favorable tolerability profile. Despite limitations from small sample sizes and lack of comparator trials, current evidence supports icatibant as a targeted, practical option for treating acute HAE attacks in children.\n <\/jats:p>","DOI":"10.2500\/aap.2026.47.260042","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:30:30Z","timestamp":1782361830000},"page":"247-252","source":"Crossref","is-referenced-by-count":2,"title":["Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review"],"prefix":"10.2500","volume":"47","author":[{"given":"Stephanie","family":"Schmalzried","sequence":"first","affiliation":[{"name":"From the Pharmacy Department, Parkview Health, Fort Wayne, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Beckett","sequence":"additional","affiliation":[{"name":"From the Pharmacy Department, Parkview Health, Fort Wayne, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Davis","sequence":"additional","affiliation":[{"name":"From the Pharmacy Department, Parkview Health, Fort Wayne, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Carreon","sequence":"additional","affiliation":[{"name":"From the Pharmacy Department, Parkview Health, Fort Wayne, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11882-017-0729-7","article-title":"Pediatric angioedema","volume":"17","author":"Pattanaik","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"B2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guidelines for the management of hereditary angioedema \u2013 the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"B4","article-title":"CSL Nehring","year":"2023"},{"key":"B5","year":"2024"},{"key":"B6","article-title":"Pharming Healthcare","year":"2020"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1111\/all.70207","article-title":"International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema","author":"Farkas","year":"2026","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"crossref","first-page":"e20160575","DOI":"10.1542\/peds.2016-0575","article-title":"Management of children with hereditary angioedema due to C1 inhibitor deficiency","volume":"138","author":"Frank","year":"2016","journal-title":"Pediatrics"},{"key":"B9","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/1346-8138.16883","article-title":"Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: a phase 3, open-label study","volume":"50","author":"Hide","year":"2023","journal-title":"J Dermatol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.jaip.2017.04.010","article-title":"Treatment effect and safety of icatibant in pediatric patients with hereditary angioedema","volume":"5","author":"Farkas","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/pai.13519","article-title":"Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema","volume":"32","author":"Farkas","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jpeds.2012.11.030","article-title":"Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children","volume":"162","author":"Lumry","year":"2013","journal-title":"J Pediatr"},{"key":"B14","year":"2024"},{"key":"B15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/pai.12444","article-title":"Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema","volume":"26","author":"Lumury","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jaip.2016.11.005","article-title":"Recombinant human C1-esterase inhibitor to treat acute hereditary angioedema attacks in adolescents","volume":"5","author":"Baker","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B17","doi-asserted-by":"crossref","first-page":"e12035","DOI":"10.1002\/clt2.12035","article-title":"Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study","volume":"11","author":"Farkas","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"B18","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/pai.13065","article-title":"Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children","volume":"30","author":"Reshef","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"B19","article-title":"Study to assess the tolerability and safety of encallantide in children and adolescents with hereditary angioedema"},{"key":"B20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13643-016-0215-7","article-title":"Comparing the coverage, recall, and precision of searches for 120 systematic reviews in Embase, MEDLINE, and Google Scholar: a prospective study","volume":"5","author":"Bramer","year":"2016","journal-title":"Syst Rev"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2026\/00000047\/00000004\/art00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:35:38Z","timestamp":1782880538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2026.47.260042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,1]]}},"alternative-id":["1088-5412(20260701)47:4L.247;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2026.47.260042","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}